Folic Acid Deficiency
Conditions
Brief summary
Folic acid supplementation has been shown previously to be associated with enhanced formation of p-HPPH from phenytoin, a metabolic pathway which is predominantly mediated through the activity of CYP2C9. The metabolism of S warfarin, the more active enantiomer of warfarin, is also mediated predominantly through the activity of CYP2C9. The purpose of the present study was to examine the relationship between folic acid concentration and warfarin pharmacokinetic as well as warfarin dose requirement among patients treated by warfarin. In addition the effect of folic acid supplementation (5 mg/d) for 3 weeks on warfarin pharmacokinetic and warfarin dose requirement will be evaluated in the second part of the study.
Interventions
DRUGFolic acid
Sponsors
Hadassah Medical Organization
Study design
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients on chronic warfarin therapy
Exclusion criteria
* Refusal to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Warfarin pharmacokinetic prior to and following administration of folic acid | — |
| Warfarin dose requirement prior to and following the administration of folic acid. | — |
Countries
Israel
Contacts
Primary ContactYoseph Caraco, MD
Outcome results
None listed